首页> 外文OA文献 >Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

【2h】

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

机译：来那度胺治疗似乎并没有增加5q缺失的低危骨髓增生异常综合征进展的风险。法国法语国家集团的比较分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Adès, Lionel; Le Bras, Fabien; Sebert, Marie; Kelaidi, Charikleia; Lamy, Thierry; Dreyfus, François; Eclache, Virginie; Delaunay, Jacques; Bouscary, Didier; Visanica, Sorin; Turlure, Pascal; Bresler, Agnès Guerci; Cabrol, Marie-Paule; Banos, Anne; Blanc, Michel; Vey, Norbert; Delmer, Alain; Wattel, Eric; Chevret, Sylvie; Fenaux, Pierre;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies | Haematologica [J] . Lionel Adès, Fabien Le Bras, Marie Sebert, Haematologica . 2012,第2期

机译：来那度胺治疗似乎并没有增加5q缺失的低危骨髓增生异常综合征进展的风险。法语国家集团骨髓病的比较分析|血液学
2. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies [J] . Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, Haematologica . 2017,第4期

机译：来那度胺联合强化化疗可治疗5q缺失的急性髓细胞白血病和高危骨髓增生异常综合征。法语国家集团的二期研究的结果
3. Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health [J] . List Alan F., Sun Zhuoxin, Verma Amit, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：来那度胺（LEN）和依泊汀阿尔法（EA）联合治疗在难治性促红细胞生成素（Epo），低风险（LR）5q [Del（5q）]骨髓增生异常综合征（MDS）患者中优于单独的来那度胺E2905组间研究（ECOG-ACRIN癌症研究组研究），格兰特CA180820，以及美国国立卫生研究院国立癌症研究所
4. A PROPOSED FRAMEWORK FOR MULTINATIONAL COMPARATIVE RISK ANALYSIS: PESTICIDE USE, IMPACTS AND MANAGEMENT Report of the Comparative Risk Assessment Methods Workgroup [C] . J.A. SHATKIN, I. ANDREAS, D.S. APUL, NATO Advanced Research Workshop on Comparative Risk Assessment and Environmental Decision Making; 20021013-20021016; Rome; IT . 2002

机译：多重比较风险分析的拟议框架：农药的使用，影响和比较风险评估方法工作组的报告
5. Aquatic toxicity, ecological risks, and risk tradeoff analysis of biocide treatment for unballasted vessels. [D] . Sano, Larissa Lubomudrov. 2005

机译：无压载船杀菌剂的水生毒性，生态风险和风险权衡分析。
6. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies [O] . Lionel Adès, Fabien Le Bras, Marie Sebert, 2012

机译：来那度胺治疗似乎并没有增加5q缺失的低危骨髓增生异常综合征进展的风险。法国法语国家集团的比较分析
7. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies [O] . Adès, Lionel, Prebet, Thomas, Stamatoullas, Aspasia, 2017

机译：来那度胺联合强化化疗可治疗急性髓样白血病和高危型骨髓增生异常综合症（5q缺失）。法语国家集团的二期研究的结果

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

著录项

引文网络

相似文献

相关主题

期刊订阅